senicapoc

These decreases were partially offset by an increase in expenses related to the development of senicapoc for asthma and a restructuring charge incurred as a result of a limited reduction in the workforce during the year.

News 2010

The decrease in operating expenses for the third quarter of 2010, as compared to the same period in 2009, was primarily due to a reduction in expenses related to the development of senicapoc for asthma, which has been discontinued.

Icagen Reports Third Quarter 2010 Financial Results and Operational Highlights - Yahoo! Finance 2010

This decrease in operating expenses was primarily due to decreased research and development costs as a result of the Company's decision to terminate the development of senicapoc for asthma, as well as decreased operating expenses resulting from the Company's ongoing cost reduction efforts.

News 2010

These decreases were partially offset by an increase in expenses related to the development of senicapoc for asthma and a restructuring charge incurred as a result of a limited reduction in the workforce during the year.

News 2010

"We are very pleased to have achieved another important milestone in the development of senicapoc for asthma," stated Seth V. Hetherington, M.D.,

News 2009

"We are very pleased to have achieved another important milestone in the development of senicapoc for asthma," stated Seth V. Hetherington, M.D.,

News 2009

Approximately 30 patients at two research centers in the United Kingdom were randomized in a 1: 1 ratio to senicapoc or placebo.

News 2009

Two separate Phase II proof-of-concept clinical trials of senicapoc as a treatment for asthma are currently ongoing, one focused on allergic asthma and the second focused on exercise-induced asthma.

News 2009

"With its novel mechanism of action, senicapoc represents a potential new oral therapy for asthma patients, and we look forward to having the results of this trial, which we expect to be available later this year."

News 2009

As previously reported, the allergen challenge trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc administered orally on pulmonary function in patients with allergic asthma following exposure to a known antigen.

News 2009